Loading
companiesCompany
CRISPR Therapeutics
CRISPR Therapeutics is the gene-editing company co-founded by Emmanuelle Charpentier that shares Casgevy with Vertex and is building off-the-shelf CAR-T cells such as CTX112 for lymphoma and autoimmune disease.
Also called: CRISPR Therapeutics AGNASDAQ:CRSP
Overview
CRISPR Therapeutics, headquartered in Zug with research in Boston, uses CRISPR/Cas9 to make gene-edited medicines. With Vertex it brought exagamglogene autotemcel (Casgevy) to approval for sickle cell disease and beta thalassaemia. In oncology it develops allogeneic CAR-T cells made from healthy donor T cells: CTX112 targets CD19 in B-cell malignancies and lupus, and CTX131 targets CD70 in solid tumours and haematological cancers. The company also has in vivo editing programmes for cardiovascular disease.
Headquarters
Zug, CH
Scorecard
All companies#415of 1244 companies, score 8
- phase 1/2 +1
- targets +2
- modalities +2
- registry trials +3
0 approved, 0 in phase 3, 1 earlier, 1 targets, 3 registry studies. Formula on the scorecards page.
Type
Cell therapy · NASDAQ:CRSP
Stage
Public
Website
Founded
2013
Phase 2CAR-T cell therapy
CTX112 is an experimental CAR-T cell therapy from CRISPR Therapeutics in phase 2 trials for hodgkin lymphoma, chronic lymphocytic leukaemia and follicular lymphoma, aimed at CD19.
drugs
Phase 2CAR-T cell therapy